These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pregnant women eligible for single-dose nevirapine study.
    Author: James JS.
    Journal: AIDS Treat News; 1997 Oct 03; (No 280):4. PubMed ID: 11364737.
    Abstract:
    ACTG 316 is testing the effectiveness of a single dose of nevirapine (Viramune) in preventing mother-to-child HIV transmission. The drug will be given to the mother during labor, and to the infant between 48 and 72 hours after birth. This placebo-controlled study allows other drugs to be taken concurrently. Women are cautioned not to rely solely on this treatment, but to also obtain standard medical care to prevent HIV transmission. There are no CD4 or viral load requirements for entry. The test will be run in several cities; enrollment information is included. If successful, nevirapine could be an easier, safer, and less expensive treatment than AZT in preventing perinatal transmission.
    [Abstract] [Full Text] [Related] [New Search]